Document is current
Any future updates will be listed below
-
Authors
Vasilevskaya, Anna http://orcid.org/0000-0001-7398-9620
Anastassiadis, Chloe
Thapa, Simrika
Taghdiri, Foad
Khodadadi, Mozhgan
Multani, Namita
Rusjan, Pablo
Ozzoude, Miracle
Tarazi, Apameh
Mushtaque, Asma
Wennberg, Richard
Houle, Sylvain
Green, Robin
Colella, Brenda
Vasdev, Neil
Blennow, Kaj
Zetterberg, Henrik
Karikari, Thomas
Sato, Christine
Moreno, Danielle
Rogaeva, Ekaterina
Mikulis, David
Davis, Karen Deborah
Tator, Charles
Tartaglia, Maria Carmela
- License Information
-
More Information
Article History
Received: 10 March 2024
Revised: 6 June 2024
Accepted: 7 July 2024
First Online: 22 July 2024
Declarations
:
: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).
